KEDBUMIN
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- KEDBUMIN
- Generic name
- ALBUMIN (HUMAN)
- Manufacturer
- Kedrion S.p.A
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 57bd6811-8619-11e0-9d78-0800200c9a66
- SPL ID
- 841fff1e-8512-4dce-aa5e-be7ed224cbf6
- Version
- 18
- Effective date
- 2026-08-20
- Source export date
- 2026-11-13
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:32:51
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125384 | derived:openfda.application_number |
| application number | BLA125384 | openfda.application_number | |
| brand name | KEDBUMIN | openfda.brand_name | |
| generic name | ALBUMIN (HUMAN) | openfda.generic_name | |
| manufacturer name | Kedrion S.p.A | openfda.manufacturer_name | |
| ndc | package | 76179-025-04 | openfda.package_ndc |
| ndc | package | 76179-025-02 | openfda.package_ndc |
| ndc | package | 76179-025-01 | openfda.package_ndc |
| ndc | package | 76179-025-03 | openfda.package_ndc |
| ndc | product | 76179-025 | openfda.product_ndc |
| ndc11 | package | 76179002503 | derived:openfda.package_ndc |
| ndc11 | package | 76179002501 | derived:openfda.package_ndc |
| ndc11 | package | 76179002502 | derived:openfda.package_ndc |
| ndc11 | package | 76179002504 | derived:openfda.package_ndc |
| rxcui | 1742222 | openfda.rxcui | |
| rxcui | 1741375 | openfda.rxcui | |
| rxcui | 1742224 | openfda.rxcui | |
| rxcui | 1741380 | openfda.rxcui | |
| spl id | 841fff1e-8512-4dce-aa5e-be7ed224cbf6 | id | |
| spl set id | 57bd6811-8619-11e0-9d78-0800200c9a66 | set_id | |
| unii | ZIF514RVZR | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5. WARNINGS AND PRECAUTIONS Risk of transmission of infectious agents ( 5.1 ). Caution where hypervolemia and its consequences or hemodilution could represent a special risk ( 5.2 ) Do not dilute with water for injection ( 5.2 ) 5.1 Hypersensitivity Hypersensitivity or allergic reactions have been observed, and may in some cases progress to severe anaphylaxis. Epinephrine should be available immediately to treat any acute hypersensitivity reaction. 5.2 Hypervolemia KEDBUMIN® should be used with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk (10). Examples of such conditions may include but are not limited to: Heart failure Arterial hypertension Esophageal varices Pulmonary edema Hemorrhagic diathesis Severe anemia Renal and post-renal anuria 5.3 Hemolysis Do not dilute KEDBUMIN® with Sterile Water for Injection, as this may cause hemolysis in recipients. There is a risk of potentially fatal hemolysis and acute renal failure from the use of Sterile Water for Injection as a diluent for 25% albumin 12 . Suitable solutions for dilution include 5% glucose and 0.9% sodium chloride (2.2). 5.4 Large Volumes When replacing comparatively large volumes of albumin, control of coagulation and hematocrit is essential. Ensure adequate substitution of other blood constituents as coagulation factors, electrolytes, platelets, and erythrocytes. 5.5 Hydration The colloid osmotic effect of KEDBUMIN® 25% is approximately four times that of human blood. Therefore, when concentrated albumin is administered, ensure adequate hydration of the patient. Carefully monitor to guard against circulatory overload (10). Hemodynamic performance should be monitored regularly. This may include arterial blood pressure and pulse rate, central venous pressure, pulmonary artery occlusion pressure, urine output, electrolyte levels, and hematocrit/hemoglobin. 5.6 Infectious Diseases Albumin is a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin. ALL infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Kedrion Biopharma, Inc. at 1-855-3KDRION (1-855-353-7466) . See also PATIENT COUNSELING INFORMATION (17) .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6. ADVERSE REACTIONS The most common adverse reactions include fever, chills, rash, nausea, vomiting, tachycardia, and hypotension ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma, Inc. at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 General The most common adverse reactions include flushing, urticaria, fever, chills, nausea, vomiting, tachycardia and hypotension. These reactions normally disappear when the infusion rate is slowed or stopped. If a severe reaction such as shock or anaphylaxis occurs, the infusion should be stopped and appropriate treatment initiated.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.